FIELD: medicine.
SUBSTANCE: disclosed is the use of a BTK (Bruton's tyrosine kinase) inhibitor for the preparation of a drug for preventing or treating optic neuromyelitis with spectral disorder, where the BTK inhibitor is a compound of formula (I). Also disclosed is the use of the BTK inhibitor for preventing recurrence of the given disease and for its treatment in a stable phase.
EFFECT: invention provides treating optic neuromyelitis with spectral disorder by using an inhibitor of BTK.
4 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF ITS USE | 2020 |
|
RU2747991C1 |
| TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS FOR USE THEREOF | 2015 |
|
RU2715421C2 |
| BTK INHIBITORS | 2020 |
|
RU2830171C1 |
| METHODS OF TREATING SJOGREN SYNDROME USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2824354C2 |
| AGONISTS OF NEUROTROPHIN RECEPTORS AND THEIR USE AS MEDICAMENTS | 2011 |
|
RU2606622C2 |
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| APPLICATION OF S1P RECEPTOR AGONIST AND METHOD OF TREATMENT, ALLEVIATION OR RETARDATION OF OPTIC NEURITIS OR DEMYELINATING DISEASES PROGRESSION | 2003 |
|
RU2391094C2 |
| NEW METHODS | 2013 |
|
RU2671495C2 |
| PYRIMIDINE DERIVATIVES AS BTK INHIBITORS AND USE THEREOF | 2016 |
|
RU2743040C2 |
| ORGANIC COMPOUNDS | 2003 |
|
RU2478378C2 |
